April 11 (Reuters) - Amgen Inc AMGN.O:
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
AMGEN INC - SAFETY PROFILE FOR IMDELLTRA WAS CONSISTENT WITH ITS KNOWN PROFILE.
AMGEN INC: GLOBAL PHASE 3 DELLPHI-304 CLINICAL TRIAL MET ITS PRIMARY ENDPOINT AT A PLANNED INTERIM ANALYSIS
AMGEN: IMDELLTRA SHOWED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS VERSUS LOCAL STANDARD-OF-CARE CHEMOTHERAPY
Source text: ID:nPn3X1N6la
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))